UnitedHealth Group
UNH
$379.09
-2.37%
UnitedHealth Group is a diversified healthcare company operating through two primary platforms: UnitedHealthcare, which provides health insurance benefits to approximately 51 million members globally, and Optum, which offers healthcare services ranging from pharmacy benefit management to outpatient care and data analytics. As one of the largest private health insurers in the United States, UnitedHealth holds a dominant market position, leveraging its integrated model to deliver cost-efficient care and capture synergies across insurance and services. The current investor narrative centers on the company's operational recovery after a challenging 2025, marked by elevated medical costs and a DOJ investigation into its Medicare billing practices, with recent quarters showing improved earnings and a strong stock rally off its lows. Debates persist over the sustainability of its growth amid regulatory scrutiny and policy dependence, while the market rotates toward defensive, value-oriented healthcare names.…
UNH
UnitedHealth Group
$379.09
Related headlines
Investment Opinion: Should I buy UNH Today?
Based on the analysis, UNH is rated a Buy. The stock offers a compelling risk-reward with a forward P/E of 17.70x, below its historical average, and an average analyst target price of $475.23, implying a 19.7% upside. The company's dominant market position, strong cash flow, and recovery from operational challenges support a positive outlook.
Sign up to view all
UNH 12-Month Price Forecast
The AI model assesses UNH as a bullish opportunity with medium confidence. The valuation is attractive on forward earnings, and the company's dominant market position and cash generation provide a solid foundation. However, the unresolved DOJ investigation and decelerating revenue growth introduce uncertainty. If the company delivers consistent earnings growth and resolves regulatory issues, the stock could re-rate higher. Conversely, any negative developments could lead to underperformance. The stance would be upgraded to high confidence if the investigation is resolved favorably and revenue growth accelerates above 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UnitedHealth Group's 12-month outlook, with a consensus price target around $475.23 and implied upside of +25.4% versus the current price.
Average Target
$475.23
0 analysts
Implied Upside
+25.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$313 - $529
Analyst target range
The target price range spans from a low of $313.00 to a high of $529.00, indicating a wide dispersion of 69% between the lowest and highest targets, reflecting significant uncertainty about the company's future. The low target of $313 implies a 21% downside, likely pricing in prolonged regulatory issues, medical cost inflation, or a recessionary impact on membership. The high target of $529 suggests a 33% upside, assuming successful resolution of the DOJ investigation, continued margin expansion, and robust growth in Optum. Recent institutional ratings have been stable, with no downgrades in the past three months, but the wide target range and ongoing legal overhang contribute to elevated uncertainty, making the stock's risk-reward profile less clear-cut despite the bullish consensus.
Bulls vs Bears: UNH Investment Factors
UnitedHealth presents a balanced risk-reward profile. The bull case is supported by a strong operational recovery, attractive forward valuation, and dominant market position, while the bear case highlights regulatory overhang, decelerating growth, and margin pressure. Currently, the evidence slightly favors the bulls given the positive earnings trajectory and analyst consensus, but the unresolved DOJ investigation and policy dependence introduce significant uncertainty. The most critical tension is whether the company can sustain its margin recovery and growth in the face of regulatory and competitive pressures, which will determine if the stock reaches its target price or falls to the bear case.
Bullish
- Strong Recovery from 52-Week Low: UNH has rallied over 55% from its 52-week low of $255.97 to $397.14, demonstrating robust operational recovery and investor confidence. The stock outperformed the S&P 500 over the past year, gaining 27.95% versus 18.65%.
- Attractive Forward Valuation: The forward P/E of 17.70x is below the 5-year average of ~22x, suggesting the stock is undervalued relative to its history. This implies the market expects significant earnings growth, with EPS projected to rise to $34.29 in the next year.
- Dominant Market Position and Scale: UnitedHealth serves approximately 51 million members globally, with a market cap of $352.7 billion. Its integrated model, combining insurance (UnitedHealthcare) and services (Optum), provides competitive advantages and cost efficiencies.
- Positive Earnings and Cash Flow: Q1 2026 net income was $6.28 billion with EPS of $6.90, and free cash flow TTM reached $19.67 billion. This strong cash generation supports dividends and buybacks, with a payout ratio of 65.7%.
Bearish
- DOJ Investigation Overhang: The ongoing DOJ investigation into Medicare billing practices creates legal and financial uncertainty. A negative outcome could result in fines, changes in billing practices, and reputational damage, potentially impacting future earnings.
- Decelerating Revenue Growth: Q1 2026 revenue grew only 1.96% YoY, a sharp deceleration from 8.9% growth in Q4 2024. This slowdown reflects pricing pressures and membership shifts, raising concerns about the company's ability to sustain growth.
- Elevated Medical Costs and Margin Pressure: The Q4 2025 net margin was nearly zero (net income of $10 million on $113.2 billion revenue), indicating severe medical cost inflation. While Q1 2026 improved, the operating margin of 8.0% is still below historical levels.
- High Valuation on Trailing Earnings: The trailing P/E of 24.95x is above the 5-year average, suggesting the stock is not cheap on current earnings. If earnings growth fails to materialize, the stock could face multiple compression.
UNH Technical Analysis
UnitedHealth's stock has exhibited a robust recovery from its 52-week low of $255.97, currently trading at $397.14, which represents 86% of the distance from the low to the 52-week high of $461.62. Over the past year, the stock has gained 27.95%, significantly outperforming the S&P 500's 18.65% return, indicating a strong longer-term uptrend. However, the stock remains 13.9% below its 52-week high, suggesting it is in a consolidation phase after a powerful rally from March to June 2026, where it surged from $285 to over $427.
Beta
0.62
0.62x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$256-$462
Price range past year
Annual Return
+7.2%
Cumulative gain past year
| Period | UNH Return | S&P 500 |
|---|---|---|
| 1m | -6.5% | -1.1% |
| 3m | -7.2% | +3.0% |
| 6m | +34.4% | +15.4% |
| 1y | +7.2% | +16.2% |
| ytd | +12.7% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNH Fundamental Analysis
UnitedHealth's revenue trajectory shows modest growth, with Q1 2026 revenue of $111.72 billion, up 1.96% year-over-year from $109.58 billion in Q1 2025. This growth rate is a deceleration from the 8.9% YoY growth seen in Q4 2024, reflecting a mature business facing pricing pressures and membership shifts. The company's revenue segments reveal that UnitedHealthcare generated $82.99 billion in Q1 2026, while OptumHealth contributed $4.58 billion, indicating the insurance arm remains the primary revenue driver, though Optum's higher-margin services are critical for profitability.
Quarterly Revenue
$111.7B
2026-03
Revenue YoY Growth
+2.0%
YoY Comparison
Gross Margin
22.7%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNH Overvalued?
Given UnitedHealth's positive net income of $6.28 billion in Q1 2026, the trailing P/E ratio of 24.95x is the most appropriate valuation metric, while the forward P/E of 17.70x indicates the market expects significant earnings growth. The gap between trailing and forward P/E implies an anticipated 41% increase in earnings per share over the next year, reflecting optimism about margin recovery and cost containment. This forward multiple is below the company's 5-year average P/E of around 22x, suggesting the stock is trading at a discount to its historical norm.
PE
25.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable. UNH's debt-to-equity ratio of 0.83 indicates moderate leverage, and the current ratio of 0.79 suggests potential liquidity concerns. The company's net margin of 2.69% is thin, and Q4 2025 showed near-zero profitability due to elevated medical costs, highlighting earnings volatility. Revenue growth decelerated to 1.96% YoY, and the business is heavily dependent on the UnitedHealthcare segment, which generates 74% of revenue, creating concentration risk. Free cash flow of $19.67 billion is strong, but the high payout ratio of 65.7% limits flexibility for reinvestment or debt reduction.